Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Vivoryon Therapeutics N.V. has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	36.43M 42.11M 34.02M 31.2M 58.69M 4.01B 59.62M 399M 157M 2.01B 158M 155M 6.64B	P/E 2026 *	-3.84x	P/E 2027 *	-3.97x
Enterprise Value	39.52M 45.68M 36.9M 33.85M 63.67M 4.35B 64.68M 433M 170M 2.18B 172M 168M 7.2B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	82.01%	Yield 2026 *	-	Yield 2027 *	-

08-06	Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026
08-06	Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-23	Vivoryon Therapeutics N.V., 2025 Earnings Call, Apr 23, 2026
04-23	Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-22	Vivoryon Therapeutics N.V. Auditor Raises 'Going Concern' Doubt	CI
03-28	Vivoryon Therapeutics N.V. Provides Update On Growing Body Of Evidence Validating Glutaminyl Cyclases As Promising Targets In DKD	CI
12-04	Vivoryon Therapeutics N.V., Q3 2025 Earnings Call, Dec 04, 2025
25-10-30	Vivoryon Therapeutics N.V. announced that it has received ?5.07075 million in funding	CI
25-10-07	Vivoryon Therapeutics Raises EUR5 Million via Private Share Placement	MT
25-09-04	Vivoryon Therapeutics N.V., H1 2025 Earnings Call, Sep 04, 2025
25-09-04	Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-17	Vivoryon Therapeutics N.V., Q1 2025 Earnings Call, Jun 17, 2025
25-05-27	Vivoryon Therapeutics Obtains Additional US Patent for Varoglutamstat	MT

08-06	Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update	GL
07-23	Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026, Annual General Meeting Planned for End of September 2026	AQ
07-22	Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026	GL
07-20	Vivoryon Therapeutics N : C. Christiansen - Vivoryon Therapeutics N.V. - Halle	PU
06-11	Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update	GL

08-06	Vivoryon boekt kleiner halfjaarverlies
08-03	Unternehmenskalender vom 3. bis 7. August 2026
07-20	Vivoryon Therapeutics N : C. Christiansen - Vivoryon Therapeutics N.V. - Halle
06-11	Verlies Vivoryon slinkt
04-26	Sterke week voor chippers op Damrak

Manager	Title	Age	Since
Frank Weber CEO	Chief Executive Officer	66	2023-08-13
Anne Doering DFI	Director of Finance/CFO	-	2024-02-29
Julia Neugebauer COO	Chief Operating Officer	-	2025-04-30

Vivoryon Therapeutics AG Stock Euronext Amsterdam

Stocks

DE0007921835

Biotechnology & Medical Research

Valuation: Vivoryon Therapeutics AG

Latest news : Vivoryon Therapeutics AG

Last Transcript: Vivoryon Therapeutics AG

Press Releases: Vivoryon Therapeutics AG

News in other languages: Vivoryon Therapeutics AG

Quotes and Performance

Managers and Directors: Vivoryon Therapeutics AG

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Charlotte Lohmann BRD	Director/Board Member	56	2006-12-31
Frank Weber BRD	Director/Board Member	66	2023-09-14
Michael Schaeffer BRD	Director/Board Member	58	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVORYON THERAPEUTICS AG	-1.26%	-.--%	-	-	42.11M
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+17.01%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+592.61%	43.97B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+73.63%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.15%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+47.53%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+122.50%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.01%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+23.95%	12.77B
Average	+1.78%	+6.32%	+85.73%	+113.30%	29.43B
Weighted average by Cap.	+2.54%	+6.10%	+105.13%	+138.38%

	2026 *	2027 *
Net sales	-	-
Net income	-8.71M -10.07M -8.13M -7.46M -14.03M -958M -14.26M -95.43M -37.46M -480M -37.81M -36.98M -1.59B	-8.71M -10.07M -8.13M -7.46M -14.03M -958M -14.26M -95.43M -37.46M -480M -37.81M -36.98M -1.59B
Net Debt	3.09M 3.57M 2.89M 2.65M 4.98M 340M 5.06M 33.86M 13.29M 170M 13.41M 13.12M 563M	11.8M 13.64M 11.02M 10.11M 19.01M 1.3B 19.32M 129M 50.74M 651M 51.23M 50.11M 2.15B